Artelo Biosciences' Lead Drug ART26.12 Shows Favorable Metabolism, De-Risking Clinical Development
ARTL is trading near its 52-week low of $1.19 (10% above the low).
Summary
Artelo Biosciences presented positive human metabolite data for its lead drug candidate, ART26.12, demonstrating a low-risk profile with only three low-level metabolites detected, all previously observed in toxicology studies. This positive clinical development news comes amidst significant financial challenges for Artelo, including a recent going concern warning in its Q1 10-Q and a series of highly dilutive financing activities. The favorable drug metabolism characteristics are critical for successful clinical development, as ADME issues are a common cause of drug failures. This data de-risks ART26.12's path forward, potentially simplifying future development, reducing timelines, and lowering costs for the company's lead pain candidate.
At the time of this announcement, ARTL was trading at $1.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6M. The 52-week trading range was $1.19 to $85.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.